Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
RCKTthis companyRocket Pharmaceuticals, Inc.	$2.45	-1.75×	1.41×	0×	-1.6×	-80.8%	0.0%	0.0%	0.0%	-80.5%	-75.4%	-48.8%	0.09×	0.25×	-120.84×	6.38×	0.0%	1	-0.82	2	C+
ANNXAnnexon, Inc.	$4.28	-3.75×	3.68×	0×	-3.14×	-80.0%	0.0%	0.0%	0.0%	-97.7%	-91.0%	-24.0%	0.12×	0.66×	0×	5.68×	0.0%	1	-1.2	2	C
AURAAura Biosciences, Inc.	$7.06	-3.1×	2.4×	0×	-2.73×	-88.8%	0.0%	0.0%	0.0%	-77.6%	-73.1%	-25.9%	0.13×	0.4×	0×	8.15×	0.0%	2	8.97	2	C+
DSGNDesign Therapeutics, Inc.	$10.55	-7.69×	2.53×	0×	-7.55×	-97.5%	0.0%	0.0%	0.0%	-32.8%	-37.1%	-10.1%	0.01×	0.22×	0×	17.14×	0.0%	1	26.54	2	C
GALTGalectin Therapeutics Inc.	$3.29	-8.67×	-2.11×	0×	-16.28×	-156.0%	0.0%	0.0%	0.0%	24.4%	-174.3%	-9.0%	-1.06×	-4.95×	-2.74×	2.42×	0.0%	2	-55.48	2	C
LBRXLB Pharmaceuticals Inc Common Stock	$42.38	-22.26×	1.87×	0×	-12.72×	-75.2%	0.0%	0.0%	0.0%	-8.4%	-9.9%	-6.3%	0.01×	9.91×	0×	41.44×	0.0%	2	25.27	2	C+
Peer median	—	-7.69×	2.4×	0×	-7.55×	-88.8%	0.0%	0.0%	0.0%	-32.8%	-73.1%	-10.1%	0.01×	0.4×	0×	8.15×	0.0%	2	8.97	2	—